Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (195)	7/10/2001 5:02:15 PM
From: nigel bates	Respond to of 1022

And PDLI still in the game. FREMONT, Calif., July 10 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) today announced that it has entered into a two-year patent rights agreement with American Home Products Corporation (NYSE: AHP - news). Under the agreement, AHP will pay a non-refundable, non-creditable upfront fee to PDL for rights to obtain a worldwide, non-exclusive license under PDL's antibody humanization patents for antibodies to a specific target antigen. Upon exercise of the rights, AHP will pay an additional fee to PDL and may pay license maintenance fees and royalties on sales of the antibodies, if any. Specific financial terms and the identity of the targeted antigen were not disclosed. Robert L. Kirkman, M.D., Vice President, Business Development and Corporate Communications for PDL, said, ``We are pleased to expand our relationships with American Home Products, which already include a patent license and humanization agreements.'' AHP currently has a non-exclusive license under PDL's antibody humanization patents to market Mylotarg (gemtuzumab ozogamicin for injection) worldwide. Mylotarg was approved in May 2000 under accelerated approval provisions by the U.S. Food and Drug Administration for the treatment of patients 60 years and older in first relapse with CD33-positive acute myeloid leukemia who are not considered candidates for cytotoxic chemotherapy. PDL receives royalties on AHP's sales of Mylotarg. In addition, PDL has humanized three antibodies for Wyeth-Ayerst Research, a division of AHP. Two of the antibodies, anti-B7-1 and anti-B7-2, are currently in Phase II clinical trials in solid organ transplantation. PDL is entitled to royalties on potential sales of these antibodies and has certain co-promotion rights. Protein Design Labs is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL holds fundamental patents in the United States, Europe and Japan for its antibody humanization technology. Further information on PDL is available at www.pdl.com.

To: keokalani'nui who wrote (195)	7/10/2001 5:28:19 PM
From: Icebrg	Respond to of 1022

Wilder, >>From collaboration in 1999 to entering clinical development 2001. That's cool.>> Mitch Sayare (IMGN's CEO) recently said in a webcast, that he is "calculating" with 18 months from target to IND for new TAPs. As those who follow IMGN know it is not always quite clear what timescale that is used in the company. But the announcement from ABGX seems to support his timeframe. Apart from that, the PR issued was not extremely informative. Neither the name of the MAB, its indication nor the size of the payment was mentioned. As far as Amgen is concerned. They did not even issue any PR. Perhaps it could be argued that this was a material event for Abgenix, but not for Amgen. I am confused. But that happens from time to time. I am used to it. Ice